SonoThera Bags $125M Series B to Advance Safer Gene Therapies

Why It Matters

By eliminating viral vectors, SonoThera could deliver safer, repeatable gene therapies, addressing a critical safety gap that has stalled several AAV‑based products.

Key Takeaways

• SonoThera raised $125 M Series B to fund non‑viral gene therapies.
• Funding backs DMD and ADPKD programs moving toward clinical trials.
• Ultrasound‑mediated delivery aims to eliminate AAV‑related liver toxicity.
• Investors include Bayer’s Leaps, Otsuka, J&J Innovation, Vertex Ventures.
• Platform promises unlimited DNA/RNA payload size and repeatable dosing.

Pulse Analysis

The gene‑therapy sector has been dominated by adeno‑associated virus (AAV) vectors, which have delivered several FDA approvals but also exposed a safety ceiling. Recent high‑profile adverse events—including multiple liver‑failure deaths linked to Sarepta’s Elevidys—have prompted regulators and investors to scrutinize the immunogenicity and dose‑limiting properties of viral carriers. As the market matures, stakeholders are seeking delivery platforms that can bypass the liver’s immune surveillance while accommodating larger genetic payloads, a need that has accelerated interest in non‑viral alternatives. These concerns have also spurred a wave of venture capital reallocations toward technologies that promise safer, repeatable dosing and broader tissue targeting.

SonoThera’s answer is an ultrasound‑mediated, non‑viral platform that uses focused acoustic energy to transiently permeabilize cell membranes, allowing direct deposition of DNA or RNA constructs. By avoiding viral capsids, the approach eliminates the liver accumulation that triggers immune reactions, and it theoretically supports payloads of unlimited size—a limitation of AAV vectors capped at ~4.7 kb. The company’s lead candidates target Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease, two indications where durable gene expression could transform standard of care. With preclinical data showing efficient transfection and minimal off‑target effects, SonoThera is poised to enter first‑in‑human trials within the next 12‑18 months.

The $125 million Series B round, led by Leaps by Bayer, Otsuka, Johnson & Johnson Innovation and other strategic investors, signals strong confidence in the commercial potential of non‑viral gene delivery. Beyond financing, these partners bring deep expertise in drug development, regulatory navigation, and global market access, which could accelerate SonoThera’s path to approval. If the platform delivers on its safety and scalability promises, it may catalyze a broader shift away from viral vectors across the biotech industry, opening new therapeutic windows for diseases previously deemed undruggable. Investors are likely to watch upcoming trial data closely, as they could reshape the valuation landscape for gene‑therapy innovators.